drugset
drugset / Trial / NCT04392219

COVID-19 First In Human Study to Evaluate Safety, Tolerability, and Pharmacokinetics of EIDD-2801 in Healthy Volunteers

NCT04392219 ↗

Phase 1 Completed 130 enrolled Ridgeback Biotherapeutics, LP
RandomizedParallel-groupDouble-blindTreatment

Summary

This is a First In Human study designed to assess the safety, tolerability and pharmacokinetics of EIDD-2801 in healthy human volunteers.

Timeline

Start
2020-04-10
Primary completion
2020-08-11
Completion
2020-08-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Molnupiravir Small molecule 50 mg Oral
Subject Molnupiravir Small molecule 200 mg Oral
Subject Molnupiravir Small molecule 1600 mg Oral

Indications

Coronaviridae infectious disease